Page 3 - Codexis Inc News Today

REDWOOD CITY, Calif., Feb. 20, 2024 -- Codexis, Inc. , a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company’s Strategic...

Paradigm Capital Management Inc. NY grew its holdings in Codexis, Inc. (NASDAQ:CDXS – Free Report) by 66.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 500,000 shares of the biotechnology company’s stock after buying an additional 200,000 shares during the quarter. Paradigm […]

The demand for diagnostic specialty enzymes will be driven by point-of-care diagnostics and infectious disease diagnostics.Wilmington, Delaware, United States, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The diagnostic specialty enzymes industry was worth US$ 1.0 billion in 2022. A CAGR of 6.9% is predicted from 2023 to 2031, leading to a market size of US$ 1.8 billion in 2031. The diagnostic specialized enzymes market is projected to experience continual technical brea

/PRNewswire/ -- The "Diagnostic Enzyme Global Market Report 2024" has been added to ResearchAndMarkets.coms offering. Global interest in healthcare...

14.02.2024 - REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) - Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February ...

Shares of Codexis, Inc. (NASDAQ:CDXS – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 1 year […]

01.02.2024 - TnX transposase development collaboration leverages strengths of both companiesBEVERLY, Mass. and REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) - seqWell, a global provider of genomic library workflow solutions, and Codexis, Inc. (NASDAQ: ... Seite 1

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The

Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The

Shares of Codexis, Inc. (NASDAQ:CDXS – Get Free Report) have received an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12-month price objective […]